|Day Low/High||20.09 / 20.65|
|52 Wk Low/High||15.15 / 35.35|
Strong Predictive Power in Both African American and Non-African American Patients
Featured Study Will Show Power of the Prolaris Test to Predict 10-Year Risk of Metastases in Men Treated for Prostate Cancer
Myriad Genetics, Spectrum Pharmaceuticals and Array BioPharma were among the biotech stock movers in early trading on Wednesday.
26 Percent Discordance Rates Observed in Public Databases
Collaboration Will Evaluate Myriad's myChoice® HRD and BRACAnalysis CDx® Tests
The Company Will Seek Reimbursement from Medicare and Private Payers
New Data Will Highlight Advances in Genetic Variant Classification for Hereditary Cancers
Second-Generation Test Provides More Accurate 10-Year Recurrence Risk for Patients Diagnosed with ER+ HER2- Early-Stage Breast Cancer
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABCO, AEGN, AVGO, GKOS, GPT, GTN, MYGN, SINO, THRM Downgrades: AN, CODI, PRGX, TAIT, TREC Initiations: BMCH Read on to get TheStreet Quant Ratings' detailed report:
Economic Utility Study Showed Annual Cost Savings of $3,988 per Member
New Data from 16,000 Patient Study to Be Presented at 2017 ASCO GU
Sage Therapeutics, Immunomedics and Myriad Genetics were among the premarket biotech stock movers on Monday.
Cramer points to Gilead's pipeline for its problems.
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Myriad Genetics, Inc. , where a total volume of 52,093 contracts has been traded thus far today, a contract volume which is representative of approximately 5.2 million underlying shares (given that every 1 contract represents 100 underlying shares).
Coverage Decisions Expand Access to More Than 32 Million Patients
The Level of Evidence for EndoPredict Consistent with that of First-Generation Test
Vectra DA Test Guides Treatment for Rheumatoid Arthritis Patients that are Methotrexate-Incomplete Responders
New Data Are Being Featured in a Podium Presentation at SABCS
New Data on EndoPredict®, myRisk™ Hereditary Cancer and myChoice® HRD